NRXP · NRX Pharmaceuticals, Inc.
$2.84
-0.03 (-1.05%)
At close · Oct 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“the Company has concluded that substantial doubt exists about the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these consolidated financial statements.”View the 10-Q filed Aug 14, 2026
Market Cap
$129.67M
Shares
43.30M
Volume · Oct 6
115.53K
Avg daily vol (3M)
884.52K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.87
Open$2.91
Day$2.79–2.93
52W close$1.68–4.62
Avg vol 30d676K
Short int9.8M · 22.6% float · 16.3d
Short vol37%
Last earningsAug 17, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 14
Up next
Next earnings call
Oct 25, 2026
Est · unconfirmed
· in 3 wks
filed Aug 14, 2026
call held Aug 17, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-12.2%
Trailing year
Short interest
22.6%
Latest settlement · 16.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Sell
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−2%
below
Price vs 50-day avg
−13%
below
RSI (14)
33
neutral
MACD trend
Negative
52-week position
40%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−18%
trailing
6-month return
+15%
trailing
YTD return
+6%
this year
Relative strength
+3%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $3 — 50d above 200d
Institutional flow
Accumulating
+37% holders QoQ · +18 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
22.57% of float · ▲ +5.1% MoM · 16.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
48 holders — near 3-yr high, broad support
Squeeze score
69
elevated · 0–100
Fundamentals
EPS growth
+70%
Y/Y
Balance sheet
$4.6M
net debt
Quant / Vol
risk profile
Volatility
86%
annualized · 1-yr
Max drawdown
−54%
past year
ATR
5.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−2%
Neutral
Price vs 50-day avg
−13%
Bearish
RSI (14)
33
Neutral
MACD trend
Negative
Bearish
52-week position
40%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $3 — 50d above 200d
Institutional flow
Accumulating
+37% holders QoQ · +18 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
22.57% of float · ▲ +5.1% MoM · 16.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
48 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $3 · 40%
Range high $5
vs 200-day avg -2%
vs 50-day avg -13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NRXP
this stock
NRX Pharmaceuticals, Inc.
|
$129.67M | +5.9% | — | — | 22.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NRXP | +0.0% | -17.8% | +14.8% | -1.7% | +5.9% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -1.2% | -18.4% | +3.2% | -3.3% | -7.7% |